Scienture (SCNX) 10-Q 27 Jul 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Jul. 24, 2020
Cover [Abstract]
Entity Registrant Name	TRXADE GROUP, INC.
Entity Central Index Key	0001382574
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,062,337
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets
Cash	$ 4,151,044	$ 2,871,694
Accounts Receivable, net	3,544,381	792,050
Inventory	1,818,874	56,761
Prepaid Assets	300,067	82,452
Deposits for Inventory purchases	309,000
Total Current Assets	10,123,366	3,802,957
Property Plant and Equipment, Net	151,397	174,987
Other Assets
Deposits	21,636	21,636
Deferred Offering Costs		88,231
Right of use leased assets	709,911	757,710
Goodwill	725,973	725,973
Total Assets	11,732,283	5,571,494
Current Liabilities
Accounts Payable	272,148	334,614
Accrued Liabilities	349,850	98,852
Current Portion Lease Liabilities	94,253	87,350
Customer Deposits	3,574
Total Current Liabilities	719,825	520,816
Long Term Liabilities
Notes Payable - Related Parties	225,000	225,000
Other Long-term Liabilities - Leases	636,081	685,461
Total Liabilities	1,580,906	1,431,277
Shareholders' Equity
Series A Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding as of June 30, 2020 and December 31, 2019, respectfully
Common Stock, $0.00001 par value; 100,000,000 shares authorized; 8,062,337 and 6,539,415 shares issued and outstanding, as of June 30, 2020 and December 31, 2019, respectively	81	65
Additional Paid-in Capital	18,909,083	12,535,655
Retained Deficit	(8,757,787)	(8,395,503)
Total Shareholders' Equity	10,151,377	4,140,217
Total Liabilities and Shareholders' Equity	$ 11,732,283	$ 5,571,494

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Series A Preferred stock, par value	$ 0.00001	$ 0.00001
Series A Preferred stock, shares authorized	10,000,000	10,000,000
Series A Preferred stock, shares issued
Series A Preferred stock, shares outstanding
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	8,062,337	6,539,415
Common stock, shares outstanding	8,062,337	6,539,415

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenues	$ 6,592,637	$ 1,916,414	$ 8,795,957	$ 3,428,935
Cost of Sales	4,587,865	753,138	5,151,049	1,118,977
Gross Profit	2,004,772	1,163,276	3,644,908	2,309,958
Operating Expenses
General and Administrative	2,540,049	1,030,571	3,991,958	2,005,494
Operating (Loss) Income	(535,277)	132,705	(347,050)	304,464
Investment Loss		(58,850)		(87,822)
Interest Expense	(7,310)	(15,874)	(15,234)	(33,432)
Net (Loss) Income	$ (542,587)	$ 57,981	$ (362,284)	$ 183,210
Net (Loss) Income per Common Share - Basic:	$ (0.07)	$ 0.01	$ (0.05)	$ 0.03
Net (Loss) Income per Common Share - Diluted:	$ (0.07)	$ 0.01	$ (0.05)	$ 0.03
Weighted average Common Shares Outstanding - Basic	7,580,977	5,621,082	7,324,512	5,591,055
Weighted average Common Shares Outstanding - Diluted	7,580,977	6,058,977	7,324,512	6,058,959

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018		$ 55	$ 8,955,688	$ (8,111,075)	$ 844,668
Balance, shares at Dec. 31, 2018		5,547,638
Common Stock issued for convertible debt and accrued interest		$ 1	211,982		211,983
Common Stock issued for convertible debt and accrued interest, shares		70,666
Warrants Exercised for Cash			166		166
Warrants Exercised for Cash, shares		2,778
Options Expense			35,979		35,979
Net Income/Loss				125,229	125,229
Balance at Mar. 31, 2019		$ 56	9,203,815	(7,985,846)	1,218,025
Balance, shares at Mar. 31, 2019		5,621,082
Balance at Dec. 31, 2018		$ 55	8,955,688	(8,111,075)	844,668
Balance, shares at Dec. 31, 2018		5,547,638
Warrant Expense
Net Income/Loss					183,210
Balance at Jun. 30, 2019		$ 56	9,267,826	(7,927,865)	1,340,017
Balance, shares at Jun. 30, 2019		5,621,082
Balance at Dec. 31, 2018		$ 55	8,955,688	(8,111,075)	844,668
Balance, shares at Dec. 31, 2018		5,547,638
Balance at Dec. 31, 2019		$ 65	12,535,655	(8,395,503)	4,140,217
Balance, shares at Dec. 31, 2019		6,539,415
Balance at Mar. 31, 2019		$ 56	9,203,815	(7,985,846)	1,218,025
Balance, shares at Mar. 31, 2019		5,621,082
Options Expense			64,011		64,011
Net Income/Loss				57,981	57,981
Balance at Jun. 30, 2019		$ 56	9,267,826	(7,927,865)	1,340,017
Balance, shares at Jun. 30, 2019		5,621,082
Balance at Dec. 31, 2019		$ 65	12,535,655	(8,395,503)	4,140,217
Balance, shares at Dec. 31, 2019		6,539,415
Warrants Exercised for Cash			1,352		1,352
Warrants Exercised for Cash, shares		22,529
Options Expense			61,997		61,997
Common Stock issued from offering		$ 10	5,994,414		5,994,424
Common Stock issued from offering, shares		922,219
Fractional shares issued due to reverse split
Fractional shares issued due to reverse split, shares		40
Stock Issuance Costs			(820,586)		(820,586)
Options Exercised for Cash			501		501
Options Exercised for Cash, shares		167
Warrant Expense			79,089		79,089
Net Income/Loss				180,303	180,303
Balance at Mar. 31, 2020		$ 75	17,852,422	(8,215,200)	9,637,297
Balance, shares at Mar. 31, 2020		7,484,370
Balance at Dec. 31, 2019		$ 65	12,535,655	(8,395,503)	4,140,217
Balance, shares at Dec. 31, 2019		6,539,415
Stock Issuance Costs					$ (820,586)
Options Exercised for Cash, shares					167
Warrant Expense					$ 100,383
Net Income/Loss					(362,284)
Balance at Jun. 30, 2020		$ 81	18,909,083	(8,757,787)	10,151,377
Balance, shares at Jun. 30, 2020		8,062,337
Balance at Mar. 31, 2020		$ 75	17,852,422	(8,215,200)	9,637,297
Balance, shares at Mar. 31, 2020		7,484,370
Warrants Exercised for Cash		$ 4	21,596		21,600
Warrants Exercised for Cash, shares		360,002
Options Expense			183,906		183,906
Warrant Expense			21,294		21,294
Common Stock Issued for Services		$ 2	829,865		829,867
Common Stock Issued for Services, shares		217,965
Net Income/Loss				(542,587)	(542,587)
Balance at Jun. 30, 2020		$ 81	$ 18,909,083	$ (8,757,787)	$ 10,151,377
Balance, shares at Jun. 30, 2020		8,062,337

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating Activities:
Net (Loss) Income	$ (362,284)	$ 183,210
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation Expense	2,500	2,500
Options expense	245,903	99,990
Warrant Expense	100,383
Common Stock issued for services	829,867
Bad Debt Expense	9,000
Investment Loss		87,822
Amortization of right to use asset	47,799	43,939
Changes in operating assets and liabilities:
Accounts Receivable	(2,761,331)	(279,852)
Prepaid Assets and other Current Assets	(217,615)	(70,119)
Inventory	(1,762,113)	(466,850)
Deposits for Inventory purchases	(309,000)
Lease Liability	(42,477)	(36,276)
Accounts Payable	(17,871)	362,599
Customer Deposits	3,574
Accrued Liabilities and Other Liabilities	250,998	(6,652)
Net Cash (used in) operating activities	(3,982,667)	(79,689)
Investing Activities:
Purchase of Fixed Assets	(23,505)
Purchase of equity method investment		(250,000)
Net Cash (used in) investing activities	(23,505)	(250,000)
Financing Activities:
Payment of Stock Issuance Costs	(732,355)
Proceeds from exercise of Warrants	22,952	166
Proceeds from exercise of Stock Options	501
Proceeds from Issuance of Common Stock	5,994,424
Net Cash provided by financing activities	5,285,522	166
Net increase (decrease) in Cash	1,279,350	(329,523)
Cash at Beginning of the Year	2,871,694	869,557
Cash at June 30, 2020 and 2019	4,151,044	540,034
Supplemental Cash Flow Information
Cash Paid for Interest	3,984	2,997
Cash Paid for Income Taxes
Non-Cash Transactions
Common Stock Issued for Conversion of Note and Accrued Interest		211,983
ROU assets and operating lease obligations recognized		$ 847,441

Organization and Basis of Prese

Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION Trxade Group, Inc. (“ we our Trxade Company Trxade, Inc., operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products. Community Specialty Pharmacy, LLC, is an accredited independent retail pharmacy with a focus on specialty medications and a community-based model offering home delivery services to patients. Alliance Pharma Solutions, LLC, has developed a same-day pharmaceutical delivery software – Delivmeds.com, and invested in SyncHealth MSO, LLC, a managed services organization during January 2019, which investment was divested in February 2020. Bonum Health, LLC was formed to hold certain telehealth assets acquired in October 2019. The “ Bonum Health Hub On October 9, 2019, the Company’s Board of Directors, and on October 15, 2019, stockholders holding a majority of the Company’s outstanding voting shares, approved resolutions authorizing a reverse stock split of the outstanding shares of the Company’s common stock in the range from one-for-two (1-for-2) to one-for-ten (1-for-10), and provided authority to the Company’s Board of Directors to select the ratio of the reverse stock split in their discretion (the “ Stockholder Authority Reverse Stock Split Proportional adjustments were made to the conversion and exercise prices of the Company’s outstanding warrants and stock options, and to the number of shares issued and issuable under the Company’s stock incentive plans in connection with the Reverse Stock Split. The Reverse Stock Split did not affect any stockholder’s ownership percentage of the Company’s common stock, except to the limited extent that the Reverse Stock Split resulted in any stockholder owning a fractional share. Fractional shares of common stock were rounded up to the nearest whole share based on each holder’s aggregate ownership of the Company. All issued and outstanding shares of common stock, options and warrants to purchase common stock and per share amounts contained in these financial statements, have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented. Basis of Presentation In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2019 as reported in the Company’s Annual Report on Form 10-K have been omitted. Income (loss) Per Common Share The following table sets forth the computation of basic and diluted Income (Loss) per Share: For three months ended For six months ended 2020 2019 2020 2019 Numerator: Net (Loss) Income $ (542,587 ) $ 57,981 $ (362,284 ) $ 183,210 Numerator for basic and diluted EPS - income available to common Shareholders (542,587 ) $ 57,981 (362,284 ) $ 183,210 Denominator: Denominator for basic EPS – Weighted average shares 7,580,977 5,621,082 7,324,512 5,591,055 Dilutive Effect of Warrants, Options and Convertible Debt - 437,877 - 467,904 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 7,580,977 6,058,959 7,324,512 6,058,959 Basic (Loss) Income per common share $ (0.07 ) $ 0.01 $ (0.05 ) $ 0.03 Diluted (Loss) Income per common share $ (0.07 ) $ 0.01 $ (0.05 ) $ 0.03

Long Term Debt - Related Partie

Long Term Debt - Related Parties	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Long Term Debt - Related Parties	NOTE 2– LONG TERM DEBT – RELATED PARTIES In October 2018, in connection with the acquisition of Community Specialty Pharmacy, LLC, a $300,000 promissory note was issued to Nikul Panchal, the seller and currently a non-executive officer of the Company, accruing simple interest at the rate of 10% per annum, payable annually, and having a maturity date in October 15, 2021. In October 2019, $75,000 of the note was converted into 25,000 common shares at $3.00 per share. There was a loss recognized on this conversion of $76,500. The outstanding balance at June 30, 2020 is $225,000.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Shareholders' Equity	NOTE 3 – SHAREHOLDERS’ EQUITY In February 2019, convertible promissory notes issued in 2015 in the amount of $181,500, were amended to include a conversion price of $3.00 per share, and the principal and accrued interest totaling $211,983 was then converted into 70,666 common shares. In February 2019, warrants to purchase 2,778 shares of common stock granted in 2014 with an exercise price of $0.06 per share were exercised for $166 in cash and the Company issued 2,778 common shares in connection with such exercise. On February 13, 2020, we entered into an underwriting agreement (the “ Underwriting Agreement Representative Offering Closing Date The Company received proceeds of approximately $5.99 million from the Offering. The Company paid the underwriters a cash fee equal to 8% of the aggregate gross proceeds received by the Company in connection with the Offering and reimbursed certain expenses. The total costs of the Offering were $820,586, including $88,213 paid in the prior year, which was included in deferred offering cost as of December 31, 2019. The net proceeds of the Offering were approximately $5.17 million. In September 2019, the Company entered into a financial consulting agreement. As compensation, the Company agreed to pay the consultant $15,000 over six months and to grant the consultant warrants to purchase 5,000 shares of common stock with an exercise price of $0.06 per share. The warrants have not been formally granted as of the date of this Report, and are expected to be formally granted in August 2020. In February 2020, warrants to purchase 22,529 shares of common stock were exercised at $0.06 per share by Nikul Panchal, a non-executive officer of the Company and note holder (see “Note 2 – Long Term Debt – Related Parties”). The Company issued 22,529 shares of common stock upon such exercise, and $1,352 in proceeds were received in connection with such exercise. In March 2020, options to purchase 167 shares of common stock were exercised at $3.00 per share; the Company issued 167 shares of common stock upon such exercise, and received $501 in proceeds. In May 2020, warrants to purchase 25,000 shares of common stock were exercised at $0.06 per share by a former consultant; the Company issued 25,000 shares of common stock upon such exercise and $1,500 in proceeds was received by the Company in connection with such exercise. On June 25, 2020, warrants to purchase 335,002 shares of common stock were exercised at $0.06 per share; the Company issued 335,002 shares of common stock upon such exercise and $20,100 in proceeds was received by the Company. 2019 Chief Executive Officer and President Bonuses On April 14, 2020, the Board of Directors of the Company (the “ Board Plan 2020 Equity Compensation Awards On April 14, 2020, the Compensation Committee approved the grant of (a) 5,000 shares of restricted common stock to the Company’s legal counsel; and (b) 12,500 shares of restricted common stock to Howard A. Doss, the Company’s Chief Financial Officer, which shares vest at the rate of 1/4th of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021. The shares have a fair value of $107,100 and the Company recognized stock-based compensation expense of $26,775 for the six months ended June 30, 2020. Independent Director Compensation Plan On April 14, 2020, the three independent members of the Board of Directors (Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson), were awarded 8,987 shares of restricted stock, which vest at the rate of 1/4th of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021. The shares have a fair value of $165,000 and the Company recognized stock-based compensation expense of $41,250 for the six months ended June 30, 2020. Employment Agreement with Suren Ajjarapu, Chief Executive Officer In connection with our employment agreement with Mr. Suren Ajjarapu, our Chief Executive Officer, which was effective on April 14, 2020, we granted 49,020 restricted shares of common stock which vest upon the Company reaching certain performance metrics established by the Compensation Committee on the same date and further amended on May 5, 2020. The fair value of the shares at the grant date was determined to be $300,000. The modification of the performance conditions resulted in an incremental value to the shares of $72,062. The Company determined that it was probable that certain performance conditions will be met and recognized compensation expense of $130,222 for the six months ended June 30, 2020.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2020
Warrants and Rights Note Disclosure [Abstract]
Warrants	NOTE 4 - WARRANTS For the six month period ended June 30, 2020, warrants to purchase 382,531 shares of common stock were exercised for proceeds of $22,952, none were granted and 8,336 expired. See “ Note 3 – Shareholders’ Equity The compensation cost related to the warrants granted in prior year was $100,383 and $0 for the six months ended June 30, 2020 and 2019, respectively. The Company’s outstanding and exercisable warrants as of June 30, 2020 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2019 524,480 $ 0.42 2.39 $ 3,273,897 Warrants granted - $ - - - Warrants expired or forfeited (8,336 ) 9.00 - - Warrants exercised (382,531 ) $ 0.06 - - Warrants Outstanding as of June 30, 2020 133,613 $ 0.94 3.91 $ 696,140 Warrants Exercisable as of June 30, 2020 63,557 $ 1.92 2.12 $ 280,007

Options

Options	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Options	NOTE 5 – OPTIONS The Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plans provide for the grant of up to 2,333,333 shares, and the Company’s 2019 Amended and Restated 2019 Equity Incentive Plan provides for automatic increases in the number of shares available under such plan (currently 2,000,000 shares) on April 1st of each calendar year, beginning in 2021 and ending in 2029 (each a “ Date of Determination For the six-month period ended June 30, 2020, options to purchase 78,770 shares were granted, none were forfeited or expired and options to purchase 167 shares of common stock were exercised, for 167 shares of common stock and proceeds of $501. The options granted during the period vest over a period ranging from less than a year to four years and have exercise prices ranging from $0.06 to $7.50 and terms ranging from 1.4 years to ten years. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the quarter ended June 30, 2020. 2020 Expected dividend yield 0 % Weighted-average expected volatility 134-236 % Weighted-average risk-free interest rate 0.25 % Expected life of options 5-7 years Total compensation cost related to stock options granted was $245,903 and $99,990 for the six months ended June 30, 2020 and 2019, respectively. The following table represents stock option activity for the six-month period ended June 30, 2020: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2019 346,998 $ 4.39 6.77 $ 817,220 Options Exercisable as of December 31, 2019 207,485 $ 5.29 5.53 $ 312,338 Options granted 78,770 $ 4.08 4.36 - Options forfeited - $ - - - Options expired - $ - - - Options exercised (167 ) $ 3.00 - - Options Outstanding as of June 30, 2020 425,601 $ 4.33 5.92 $ 801,715 Options Exercisable as of June 30, 2020 243,668 $ 5.09 5.42 $ 286,011

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	NOTE 6 – CONTINGENCIES In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu and Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine, certain unrelated persons (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleges causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint relates to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The complaint seeks $425,000 in compensatory damages and $1,275,000 in punitive damages. The Company and Mr. Ajjarapu deny in their entirety the plaintiffs’ allegations and filed a motion to dismiss the plaintiffs’ claims against the Company and Mr. Ajjarapu, which motion was granted in May 2020, due to the plaintiffs’ not being able to establish personal jurisdiction over the defendants, which motion was successful as to all defendants. The Company and Mr. Ajjarapu further refute any connections for the purpose of the suit to the other named defendants. To the Company’s and Mr. Ajjarapu’s knowledge, the complaint has no merit whatsoever and, to the extent the motion to dismiss is reversed or the plaintiffs’ appeal, each of the Company and Mr. Ajjarapu intend to vigorously defend themselves and oppose the relief sought in the complaint. The Company is unable to determine the estimate of the probable or reasonable possible loss or range of losses arising from the above legal proceeding. The final date for the plaintiffs to appeal the ruling to dismiss the lawsuit is in August 2020.

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	NOTE 7 – LEASES The Company elected the practical expedient under ASU 2018-11 “ Leases: Targeted Improvements Lease 1 Lease 2 Initial Lease Term December 2017 to January 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 % The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of June 30, 2020. Amounts due within twelve months of June 30 2020 $ 163,102 2021 167,984 2022 173,038 2023 178,237 2024 117,259 Thereafter 187,752 Total minimum lease payments 987,372 Less: effect of discounting (257,038 ) Present value of future minimum lease payments 730,334 Less: current obligations under leases 94,253 Long-term lease obligations $ 636,081 For the six months ended June 30, 2020 and 2019, amortization of assets was $47,799 and $43,939, respectively. For the six months ended June 30, 2020 and 2019, amortization of liabilities was $42,477 and $36,276, respectively.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	NOTE 8 – SEGMENT REPORTING The Company classifies its business interests into reportable segments which are Trxade, Inc., Community Specialty Pharmacy, LLC, Integra Pharma, LLC and Other. Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment. Six Months Ended June 30, 2020 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 2,914,537 $ 870,637 $ 5,003,523 $ 7,260 $ 8,795,957 Gross Profit $ 2,914,537 $ 74,835 $ 648,276 $ 7,260 $ 3,644,908 Segment Assets $ 1,793,747 $ 243,603 $ 5,041,989 $ 4,652,944 $ 11,732,283 Segment Profit (Loss) $ 1,872,862 $ (72,955 ) $ 369,370 $ (2,531,561 ) $ (362,284 ) Six Months Ended June 30, 2019 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 2,182,668 $ 892,357 $ 353,910 $ - $ 3,428,935 Gross Profit $ 2,182,668 $ 111,977 $ 15,313 $ - $ 2,309,958 Segment Assets $ 1,401,724 $ 224,863 $ 834,082 $ 1,217,396 $ 3,678,065 Segment Profit (Loss) $ 1,166,543 $ (61,628 ) $ (143,882 ) $ (777,823 ) $ 183,210

Equity Method Investment

Equity Method Investment	6 Months Ended
	Jun. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	NOTE 9 – EQUITY METHOD INVESTMENT In January 2019, the Company, through its wholly-owned subsidiary Alliance Pharma Solution, LLC (“ Alliance SyncHealth PanOptic

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS Return of Inventory Deposits In July 2020, $226,500 of inventory deposits were returned to the Company as the providers were out of stock of the specific product ordered.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Basic and Dilutive Income (Loss) Per Share	The following table sets forth the computation of basic and diluted Income (Loss) per Share: For three months ended For six months ended 2020 2019 2020 2019 Numerator: Net (Loss) Income $ (542,587 ) $ 57,981 $ (362,284 ) $ 183,210 Numerator for basic and diluted EPS - income available to common Shareholders (542,587 ) $ 57,981 (362,284 ) $ 183,210 Denominator: Denominator for basic EPS – Weighted average shares 7,580,977 5,621,082 7,324,512 5,591,055 Dilutive Effect of Warrants, Options and Convertible Debt - 437,877 - 467,904 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 7,580,977 6,058,959 7,324,512 6,058,959 Basic (Loss) Income per common share $ (0.07 ) $ 0.01 $ (0.05 ) $ 0.03 Diluted (Loss) Income per common share $ (0.07 ) $ 0.01 $ (0.05 ) $ 0.03

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Warrants and Rights Note Disclosure [Abstract]
Schedule of Outstanding and Exercisable Warrants	The Company’s outstanding and exercisable warrants as of June 30, 2020 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2019 524,480 $ 0.42 2.39 $ 3,273,897 Warrants granted - $ - - - Warrants expired or forfeited (8,336 ) 9.00 - - Warrants exercised (382,531 ) $ 0.06 - - Warrants Outstanding as of June 30, 2020 133,613 $ 0.94 3.91 $ 696,140 Warrants Exercisable as of June 30, 2020 63,557 $ 1.92 2.12 $ 280,007

Options (Tables)

Options (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Estimate Fair Value of Stock Options	The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the quarter ended June 30, 2020. 2020 Expected dividend yield 0 % Weighted-average expected volatility 134-236 % Weighted-average risk-free interest rate 0.25 % Expected life of options 5-7 years
Schedule of Stock Option Activity	The following table represents stock option activity for the six-month period ended June 30, 2020: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2019 346,998 $ 4.39 6.77 $ 817,220 Options Exercisable as of December 31, 2019 207,485 $ 5.29 5.53 $ 312,338 Options granted 78,770 $ 4.08 4.36 - Options forfeited - $ - - - Options expired - $ - - - Options exercised (167 ) $ 3.00 - - Options Outstanding as of June 30, 2020 425,601 $ 4.33 5.92 $ 801,715 Options Exercisable as of June 30, 2020 243,668 $ 5.09 5.42 $ 286,011

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of Operating Leases	The following table outlines the details: Lease 1 Lease 2 Initial Lease Term December 2017 to January 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 %
Schedule of Future Minimum Payments for Operating Lease Liabilities	The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of June 30, 2020. Amounts due within twelve months of June 30 2020 $ 163,102 2021 167,984 2022 173,038 2023 178,237 2024 117,259 Thereafter 187,752 Total minimum lease payments 987,372 Less: effect of discounting (257,038 ) Present value of future minimum lease payments 730,334 Less: current obligations under leases 94,253 Long-term lease obligations $ 636,081

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Schedule of Business Interests Into Reportable Segments	The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment. Six Months Ended June 30, 2020 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 2,914,537 $ 870,637 $ 5,003,523 $ 7,260 $ 8,795,957 Gross Profit $ 2,914,537 $ 74,835 $ 648,276 $ 7,260 $ 3,644,908 Segment Assets $ 1,793,747 $ 243,603 $ 5,041,989 $ 4,652,944 $ 11,732,283 Segment Profit (Loss) $ 1,872,862 $ (72,955 ) $ 369,370 $ (2,531,561 ) $ (362,284 ) Six Months Ended June 30, 2019 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 2,182,668 $ 892,357 $ 353,910 $ - $ 3,428,935 Gross Profit $ 2,182,668 $ 111,977 $ 15,313 $ - $ 2,309,958 Segment Assets $ 1,401,724 $ 224,863 $ 834,082 $ 1,217,396 $ 3,678,065 Segment Profit (Loss) $ 1,166,543 $ (61,628 ) $ (143,882 ) $ (777,823 ) $ 183,210

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details Narrative)	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%
Reverse stock split, description	On October 9, 2019, the Company's Board of Directors, and on October 15, 2019, stockholders holding a majority of the Company's outstanding voting shares, approved resolutions authorizing a reverse stock split of the outstanding shares of the Company's common stock in the range from one-for-two (1-for-2) to one-for-ten (1-for-10), and provided authority to the Company's Board of Directors to select the ratio of the reverse stock split in their discretion (the "Stockholder Authority"). On February 12, 2020, the Board of Directors of the Company approved a stock split ratio of 1-for-6 ("Reverse Stock Split") in connection with the Stockholder Authority and the Company filed a Certificate of Amendment with the Secretary of Delaware to effect the Reverse Stock Split.

Organization and Basis of Pre_4

Organization and Basis of Presentation - Schedule of Basic and Dilutive Income (Loss) Per Share (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net (Loss) Income	$ (542,587)	$ 180,303	$ 57,981	$ 125,229	$ (362,284)	$ 183,210
Numerator for basic and diluted EPS - income available to common Shareholders	$ (542,587)		$ 57,981		$ (362,284)	$ 183,210
Denominator for basic EPS – Weighted average shares	7,580,977		5,621,082		7,324,512	5,591,055
Dilutive Effect of Warrants, Options and Convertible Debt			437,877			467,904
Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions	7,580,977		6,058,977		7,324,512	6,058,959
Basic (Loss) Income per common share	$ (0.07)		$ 0.01		$ (0.05)	$ 0.03
Diluted (Loss) Income per common share	$ (0.07)		$ 0.01		$ (0.05)	$ 0.03

Long Term Debt - Related Part_2

Long Term Debt - Related Parties (Details Narrative) - USD ($)	1 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jun. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Long term debt related party			$ 225,000	$ 225,000
Community Specialty Pharmacy, LLC [Member] | Related Party Promissory Note [Member] | Nikul Panchal [Member]
Debt Instrument [Line Items]
Proceeds from issuance of promissory note		$ 300,000
Interest rate		10.00%
Debt instrument maturity date		Oct. 15, 2021
Debt instrument conversion amount	$ 75,000
Debt instrument conversion shares	25,000
Debt instrument conversion price per share		$ 3
Loss on extinguishment of debt	$ 76,500

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)

Jun. 25, 2020

Apr. 14, 2020

Mar. 31, 2020

Feb. 29, 2020

Feb. 21, 2020

Feb. 18, 2020

Feb. 13, 2020

May 31, 2020

Sep. 30, 2019

Feb. 28, 2019

Mar. 31, 2020

Jun. 30, 2020

Jun. 30, 2019

Dec. 31, 2019

Class of Stock [Line Items]

Warrants to purchase common stock

335,002

2,778

Warrant exercise price

$ 0.06

$ 0.06

Number of warrants exercised for cash

$ 166

Number of common shares issued for warrants exercised

2,778

Stock issued during period

335,002

Proceeds from offering

$ 5,990,000

Underwriters cash fee percentage

8.00%

Stock offering costs

$ 820,586

$ 820,586

Deferred offering costs

$ 88,213

Net issuance cost

5,170,000

Stock based compensation

$ 245,903

$ 99,990

Common stock issued upon exercise

167

Proceeds of stock exercised

$ 501

Number of options, granted

78,770

Proceeds from issuance of common stock

$ 20,100

$ 5,994,424

Legal Counsel [Member]

Class of Stock [Line Items]

Restricted common stock

5,000

Two Thousand Twenty Equity Compensation Awards [Member]

Class of Stock [Line Items]

Stock based compensation

$ 107,100

26,775

Independent Director Compensation Plan [Member]

Class of Stock [Line Items]

Stock based compensation

165,000

41,250

2019 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Stock based compensation

$ 761,842

Former Consultant [Member]

Class of Stock [Line Items]

Warrants to purchase common stock

25,000

Warrant exercise price

$ 0.06

Stock issued during period

25,000

Proceeds from issuance of common stock

$ 1,500

Aijarapu [Member] | 2019 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Stock issued during period

74,484

Bonus description

Company's Chief Executive Officer and Prashant Patel, the Company's President, of bonuses equal to 1% of the Company's outstanding shares, equivalent to 74,484 shares of common stock

Mr. Patel [Member] | 2019 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Stock issued during period

50,000

Howard A. Doss [Member]

Class of Stock [Line Items]

Compensation awards description

Shares vest at the rate of 1/4th of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021

Restricted common stock

12,500

Mr. Donald G. Fell, Dr. Pamela Tenaerts and Mr. Michael L. Peterson [Member]

Class of Stock [Line Items]

Restricted common stock

8,987

Underwriting Agreement [Member] | Underwriters [Member]

Class of Stock [Line Items]

Sale of common stock

$ 806,452

Financial Consulting Agreement [Member] | Nikul Panchal [Member]

Class of Stock [Line Items]

Warrants to purchase common stock

22,529

Warrant exercise price

$ 0.06

Common stock issued upon exercise

22,529

Proceeds of stock exercised

$ 1,352

Financial Consulting Agreement [Member] | Consultant [Member]

Class of Stock [Line Items]

Warrants to purchase common stock

167

5,000

167

Warrant exercise price

$ 3

$ 0.06

$ 3

Stock based compensation

$ 15,000

Common stock issued upon exercise

167

Financial Consulting Agreement [Member] | Private Placement [Member] | Consultant [Member]

Class of Stock [Line Items]

Proceeds of stock exercised

$ 501

Employment Agreement [Member]

Class of Stock [Line Items]

Stock based compensation

$ 130,222

Employment Agreement [Member] | Mr. Ajjarapu [Member]

Class of Stock [Line Items]

Number of options, granted

300,000

Restricted common stock

49,020

Incremental value to the shares

72,062

Representative [Member] | Underwriting Agreement [Member] | Offering [Member]

Class of Stock [Line Items]

Sale of common stock

$ 806,452

Sale of stock price per share

$ 6.50

Representative [Member] | Underwriting Agreement [Member] | Over-Allotment Option [Member]

Class of Stock [Line Items]

Stock issued during period

115,767

Convertible Promissory Note [Member]

Class of Stock [Line Items]

Convertible promissory notes

$ 181,500

Debt instrument conversion price per share

$ 3

Debt principal and accrued interest, amount

$ 211,983

Debt instrument conversion shares

70,666

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 25, 2020	Feb. 28, 2019
Class of Warrant or Right [Line Items]
Warrants to purchase common stock			335,002	2,778
Proceeds from exercise of warrants	$ 22,952	$ 166
Warrants granted
Stock based compensation	$ 245,903	99,990
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase common stock	382,531
Proceeds from exercise of warrants	$ 22,952
Warrants granted
Warrants expired	8,336
Stock based compensation	$ 100,383	$ 0

Warrants - Schedule of Outstand

Warrants - Schedule of Outstanding and Exercisable Warrants (Details)	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Warrants and Rights Note Disclosure [Abstract]
Number of Outstanding Shares, Warrants Outstanding Beginning | shares	524,480
Number of Outstanding Shares, Warrants Granted | shares
Number of Outstanding Shares, Warrants Expired or Forfeited | shares	(8,336)
Number of Outstanding Shares, Warrants Exercised | shares	(382,531)
Number of Outstanding Shares, Warrants Outstanding Ending | shares	133,613
Number of Outstanding Shares, Warrants Exercisable Ending | shares	63,557
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 0.42
Weighted Average Exercise Price, Warrants Granted | $ / shares
Weighted Average Exercise Price, Warrants Expired or Forfeited | $ / shares	9
Weighted Average Exercise Price, Warrants Exercised | $ / shares	0.06
Weighted Average Exercise Price, Outstanding Ending | $ / shares	0.94
Weighted Average Exercise Price, Warrants Exercisable Ending | $ / shares	$ 1.92
Contractual Life Warrants Outstanding, Beginning	2 years 4 months 20 days
Contractual Life Warrants Outstanding, Granted	0 years
Contractual Life Warrants Outstanding, Expired or Forfeited	0 years
Contractual Life Warrants Outstanding, Exercised	0 years
Contractual Life Warrants Outstanding Ending	3 years 10 months 28 days
Contractual Life Warrants, Warrants Exercisable Ending	2 years 1 month 13 days
Aggregate Intrinsic Value Outstanding Beginning | $	$ 3,273,897
Aggregate Intrinsic Value Outstanding Ending | $	696,140
Aggregate Intrinsic Value Warrants Exercisable Ending | $	$ 280,007

Options (Details Narrative)

Options (Details Narrative) - USD ($)	Jun. 25, 2020	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted		78,770
Number of shares available	335,002
Number of Options, Forfeited
Number of Options, Expired
Common stock issued upon exercise		167
Proceeds from common stock	$ 20,100	$ 5,994,424
Options description		The options granted during the period vest over a period ranging from less than a year to four years and have exercise prices ranging from $0.06 to $7.50 and terms ranging from 1.4 years to ten years.
Options exercise prices		$ 3
Stock options, compensation cost		$ 245,903	$ 99,990
Common Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available		167
Proceeds from common stock		$ 501
Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted		2,333,333
2019 Amended and Restated 2019 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available		2,000,000
Shares description		The Company's 2019 Amended and Restated 2019 Equity Incentive Plan provides for automatic increases in the number of shares available under such plan (currently 2,000,000 shares) on April 1st of each calendar year, beginning in 2021 and ending in 2029 (each a "Date of Determination"), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator.

Options - Schedule of Estimate

Options - Schedule of Estimate Fair Value of Stock Options (Details)	6 Months Ended
	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%
Weighted-average expected volatility, minimum	134.00%
Weighted-average expected volatility, maximum	236.00%
Weighted-average risk-free interest rate	0.25%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	7 years

Options - Schedule of Stock Opt

Options - Schedule of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Share-based Payment Arrangement [Abstract]
Number of Options Outstanding, Beginning Balance | shares	346,998
Number of Options Exercisable, Beginning Balance | shares	207,485
Number of Options, Granted | shares	78,770
Number of Options, Forfeited | shares
Number of Options, Expired | shares
Number of Options, Exercised | shares	(167)
Number of Options Outstanding, Ending Balance | shares	425,601
Number of Options Exercisable, Ending Balance | shares	243,668
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 4.39
Weighted Average Exercise Price Exercisable, Beginning Balance | $ / shares	5.29
Weighted Average Exercise Price, Granted | $ / shares	4.08
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Expired | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares	3
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	4.33
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 5.09
Contractual Life in Years Outstanding, Beginning Balance	6 years 9 months 7 days
Contractual Life in Years Exercisable, Beginning Balance	5 years 6 months 10 days
Contractual Life in Years, Granted	4 years 4 months 9 days
Contractual Life in Years, Forfeited	0 years
Contractual Life in Years, Expired	0 years
Contractual Life in Years, Exercised	0 years
Contractual Life in Years Outstanding, Ending Balance	5 years 11 months 1 day
Contractual Life in Years Exercisable, Ending Balance	5 years 5 months 1 day
Intrinsic Value Outstanding, Beginning Balance | $	$ 817,220
Intrinsic Value Exercisable, Beginning Balance | $	312,338
Intrinsic Value, Exercised | $
Intrinsic Value Outstanding, Ending Balance | $	801,715
Intrinsic Value Exercisable, Ending Balance | $	$ 286,011

Contingencies (Details Narrativ

Contingencies (Details Narrative)	1 Months Ended
	Jan. 31, 2020USD ($)
Compensatory Damages [Member]
Complaint seeks	$ 425,000
Punitive Damages [Member]
Complaint seeks	$ 1,275,000

Leases (Details Narrative)

Leases (Details Narrative)	6 Months Ended
	Jun. 30, 2020USD ($)Integer	Jun. 30, 2019USD ($)
Leases [Abstract]
Operating leases units | Integer	2
Operating lease amortization of right of use lease assets	$ 47,799	$ 43,939
Operating lease liabilities paid	$ 42,477	$ 36,276

Leases - Schedule of Operating

Leases - Schedule of Operating Leases (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Initial Recognition of Right to use assets at January 1, 2019	$ 709,911	$ 757,710
Lease 1 [Member]
Lessee, Lease, Description [Line Items]
Initial Lease Term	December 2017 to January 2021
Renewal Term	January 2021 to December 2024
Initial Recognition of Right to use assets at January 1, 2019	$ 534,140
Incremental Borrowing Rate	10.00%
Lease 2 [Member]
Lessee, Lease, Description [Line Items]
Initial Lease Term	November 2018 to November 2023
Renewal Term	November 2023 to November 2028
Initial Recognition of Right to use assets at January 1, 2019	$ 313,301
Incremental Borrowing Rate	10.00%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments for Operating Lease Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
2020	$ 163,102
2021	167,984
2022	173,038
2023	178,237
2024	117,259
Thereafter	187,752
Total minimum lease payments	987,372
Less: effect of discounting	(257,038)
Present value of future minimum lease payments	730,334
Less: current obligations under leases	94,253	$ 87,350
Long-term lease obligations	$ 636,081	$ 685,461

Segment Reporting - Schedule of

Segment Reporting - Schedule of Business Interests Into Reportable Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 6,592,637	$ 1,916,414	$ 8,795,957	$ 3,428,935
Gross Profit	2,004,772	1,163,276	3,644,908	2,309,958
Segment Assets	11,732,283	3,678,065	11,732,283	3,678,065	$ 5,571,494
Segment Profit (Loss)			(362,284)	183,210
Trxade, Inc. [Member]
Segment Reporting Information [Line Items]
Revenue			2,914,537	2,182,668
Gross Profit			2,914,537	2,182,668
Segment Assets	1,793,747	1,401,724	1,793,747	1,401,724
Segment Profit (Loss)			1,872,862	1,166,543
Community Specialty Pharmacy, LLC [Member]
Segment Reporting Information [Line Items]
Revenue			870,637	892,357
Gross Profit			74,835	111,977
Segment Assets	243,603	224,863	243,603	224,863
Segment Profit (Loss)			(72,955)	(61,628)
Integra Pharma, LLC [Member]
Segment Reporting Information [Line Items]
Revenue			5,003,523	353,910
Gross Profit			648,276	15,313
Segment Assets	5,041,989	834,082	5,041,989	834,082
Segment Profit (Loss)			369,370	(143,882)
Other [Member]
Segment Reporting Information [Line Items]
Revenue			7,260
Gross Profit			7,260
Segment Assets	$ 4,652,944	$ 1,217,396	4,652,944	1,217,396
Segment Profit (Loss)			$ (2,531,561)	$ (777,823)

Equity Method Investment (Detai

Equity Method Investment (Details Narrative) - USD ($)	Jun. 25, 2020	Apr. 30, 2019	Jan. 31, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Jan. 31, 2020	Nov. 01, 2019	Aug. 01, 2019	May 01, 2019
Schedule of Equity Method Investments [Line Items]
Payment to acquire equity interest						$ 250,000
Equity method investment ownership percentage					100.00%
Stock issued during period	335,002
Investment loss recognized					$ 87,822		$ 250,000
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued during period							378,888
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Stock issued during period							2,462,773
SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage									7.00%	6.00%	6.00%
Alliance Pharma Solution, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Payment to acquire equity interest		$ 40,000	$ 250,000	$ 210,000
Equity method investment ownership percentage			30.00%
Alliance Pharma Solution, LLC [Member] | SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage			30.00%				30.00%
PanOptic Health, LLC [Member] | SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage			70.00%					30.00%
SyncHealth MSO, LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage								51.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Jul. 31, 2020USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Inventory deposits	$ 226,500